Compare Stocks → Thousands of investors use this no cost solution | Do you? (From Insider Financial) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison OTCMKTS:EMISNASDAQ:FLXNNYSE:KDMNNASDAQ:MTEMNASDAQ:RAPT Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEMISEmisphere Technologies$7.81$7.81$4.06▼$9.16N/AN/AN/AN/AFLXNFlexion Therapeutics$9.12$9.20$4.30▼$13.66$458.93M1.531.18 million shsN/AKDMNKadmon$9.50$9.50$3.19▼$9.50$1.70BN/A5.11 million shs1,052 shsMTEMMolecular Templates$1.53+2.0%$2.71$1.40▼$9.45$8.22M1.1552,706 shs11,072 shsRAPTRAPT Therapeutics$8.09+2.9%$10.28$6.86▼$27.35$281.53M0.471.17 million shs139,262 shs(Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEMISEmisphere Technologies0.00%0.00%0.00%0.00%0.00%FLXNFlexion Therapeutics0.00%0.00%0.00%0.00%0.00%KDMNKadmon0.00%0.00%0.00%0.00%0.00%MTEMMolecular Templates+2.04%-15.73%-18.92%-57.75%-76.74%RAPTRAPT Therapeutics-1.13%-7.96%-5.64%-68.76%-60.22%Thousands of investors use this no cost solution | Do you? (Ad)In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.Simply tap here now to subscribe and start getting "Insider Financial Advantage"MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEMISEmisphere TechnologiesN/AN/AN/AN/AN/AN/AN/AN/AFLXNFlexion TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AKDMNKadmonN/AN/AN/AN/AN/AN/AN/AN/AMTEMMolecular Templates1.1743 of 5 stars0.03.00.04.60.64.20.0RAPTRAPT Therapeutics4.3522 of 5 stars4.34.00.03.61.41.70.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEMISEmisphere TechnologiesN/AN/AN/AN/AFLXNFlexion TherapeuticsN/AN/AN/AN/AKDMNKadmonN/AN/AN/AN/AMTEMMolecular TemplatesN/AN/AN/AN/ARAPTRAPT Therapeutics2.50Moderate Buy$25.67217.26% UpsideCurrent Analyst RatingsLatest MTEM, KDMN, FLXN, EMIS, and RAPT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/10/2024RAPTRAPT TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral3/27/2024RAPTRAPT TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$15.00 ➝ $13.002/22/2024RAPTRAPT TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$61.00 ➝ $10.002/21/2024RAPTRAPT TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform2/21/2024RAPTRAPT TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$35.00 ➝ $13.002/21/2024RAPTRAPT TherapeuticsSVB LeerinkSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform$42.00 ➝ $10.002/21/2024RAPTRAPT TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Neutral$35.00 ➝ $15.002/21/2024RAPTRAPT TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral2/20/2024RAPTRAPT TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Neutral2/16/2024RAPTRAPT TherapeuticsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEMISEmisphere TechnologiesN/AN/AN/AN/AN/AN/AFLXNFlexion Therapeutics$85.55M5.36N/AN/A($0.34) per share-26.82KDMNKadmonN/AN/AN/AN/AN/AN/AMTEMMolecular Templates$57.31M0.14N/AN/A$0.78 per share1.96RAPTRAPT Therapeutics$1.53M184.01N/AN/A$4.27 per share1.89Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEMISEmisphere TechnologiesN/AN/A0.00∞N/AN/AN/AN/AN/AFLXNFlexion Therapeutics-$113.71M-$2.01N/AN/AN/A-100.32%N/A-44.26%N/AKDMNKadmonN/AN/A0.00∞N/AN/AN/AN/AN/AMTEMMolecular Templates-$8.12M-$1.55N/AN/AN/A-14.18%-9,335.53%-20.51%5/20/2024 (Estimated)RAPTRAPT Therapeutics-$116.80M-$3.04N/AN/AN/AN/A-63.14%-55.48%5/9/2024 (Estimated)Latest MTEM, KDMN, FLXN, EMIS, and RAPT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/7/2024Q4 2023RAPTRAPT Therapeutics-$0.85-$0.80+$0.05-$0.80N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEMISEmisphere TechnologiesN/AN/AN/AN/AN/AFLXNFlexion TherapeuticsN/AN/AN/AN/AN/AKDMNKadmonN/AN/AN/AN/AN/AMTEMMolecular TemplatesN/AN/AN/AN/AN/ARAPTRAPT TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEMISEmisphere TechnologiesN/AN/AN/AFLXNFlexion TherapeuticsN/A4.384.05KDMNKadmonN/AN/AN/AMTEMMolecular TemplatesN/A0.970.97RAPTRAPT TherapeuticsN/A7.417.41OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEMISEmisphere TechnologiesN/AFLXNFlexion Therapeutics90.01%KDMNKadmonN/AMTEMMolecular Templates95.47%RAPTRAPT Therapeutics99.09%Insider OwnershipCompanyInsider OwnershipEMISEmisphere Technologies72.90%FLXNFlexion Therapeutics9.13%KDMNKadmonN/AMTEMMolecular Templates13.40%RAPTRAPT Therapeutics6.60%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableEMISEmisphere Technologies6N/AN/ANot OptionableFLXNFlexion Therapeutics25750.32 million45.73 millionOptionableKDMNKadmonN/A178.52 millionN/AOptionableMTEMMolecular Templates1115.37 million4.65 millionNo DataRAPTRAPT Therapeutics13134.80 million32.50 millionOptionableMTEM, KDMN, FLXN, EMIS, and RAPT HeadlinesSourceHeadlineRAPT Therapeutics gets grant for inhibiting hematopoietic progenitor kinase 1 using pyrazole pyrimidine compoundspharmaceutical-technology.com - April 18 at 9:25 AMVertex buying Alpine for $4.9B for phase III-ready IgAN assetbioworld.com - April 12 at 8:27 AMHold Rating on RAPT Therapeutics Amid Promising Data and Regulatory Uncertaintiesmarkets.businessinsider.com - April 12 at 8:27 AMRAPT reports positive phase 2 cancer trial resultsinvesting.com - April 11 at 1:51 AMMaintaining Hold Rating on RAPT Therapeutics Amidst Mixed Clinical Results and Regulatory Uncertaintymarkets.businessinsider.com - April 10 at 8:50 PMRAPT Therapeutics (NASDAQ:RAPT) Earns Neutral Rating from HC Wainwrightmarketbeat.com - April 10 at 8:17 AMRAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patientsglobenewswire.com - April 9 at 12:00 PMRapt Creative's glimpse of the past and nod to the futurebizcommunity.com - April 9 at 7:40 AM3 Biotech Stocks to Dump Before They Go to Zeroinvestorplace.com - April 9 at 6:31 AMRAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Consensus Recommendation of "Moderate Buy" from Analystsmarketbeat.com - April 4 at 2:31 AMShort Interest in RAPT Therapeutics, Inc. (NASDAQ:RAPT) Rises By 32.5%marketbeat.com - April 1 at 8:31 AMRAPT Therapeutics (NASDAQ:RAPT) Price Target Cut to $13.00marketbeat.com - March 27 at 10:59 AMFringe paceman Gannon savours WA's Shield three-peatillawarramercury.com.au - March 26 at 9:02 AMRAPT Apr 2024 10.000 putfinance.yahoo.com - March 16 at 8:39 AMSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of RAPT Therapeutics, Inc. - RAPTprnewswire.com - March 11 at 6:06 PMLeap To Fame on his way to defending Grand Circuit titleharnesslink.com - March 11 at 8:04 AMHold Rating on RAPT Therapeutics Amid Clinical Trial Uncertainties and Financial Concernsmarkets.businessinsider.com - March 11 at 8:04 AMRAPT Oct 2024 5.000 callfinance.yahoo.com - March 8 at 12:09 AMRAPT Stock Earnings: RAPT Therapeutics Beats EPS for Q4 2023investorplace.com - March 7 at 5:03 PMShould You Buy RAPT Therapeutics (RAPT) Ahead of Earnings?zacks.com - March 7 at 9:41 AMRAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Resultsglobenewswire.com - March 7 at 8:00 AMRAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meetingglobenewswire.com - March 5 at 4:30 PMSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of RAPT Therapeutics, Inc. - RAPTprnewswire.com - March 3 at 10:15 AMRAPT Therapeutics, Inc. (RAPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoingsbusinesswire.com - February 26 at 4:00 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsEmisphere TechnologiesOTCMKTS:EMISEmisphere Technologies, Inc. operates as a commercial stage pharmaceutical and drug delivery company in the United States. The company offers oral Eligen B12 Rx, an oral formulation prescription medical food for use by B12 deficient individuals. It is also developing GLP-1, which is in Phase III clinical trial for the treatment of type 2 diabetes and related conditions. The company's preclinical programs focus on the development of oral formulations for the treatment of diabetes; and products in the areas of cardiovascular, appetite suppression, and pain, as well as in the development and expansion of nutritional supplement products. It has license agreements with Novo Nordisk A/S to develop and commercialize oral formulations of GLP-1 receptor agonists in combination with Emisphere carriers, as well as to develop and commercialize oral formulations of Novo Nordisk's insulin using the company's Eligen Technology. The company was formerly known as Clinical Technologies Associates, Inc. and changed its name to Emisphere Technologies, Inc. in 1991. Emisphere Technologies, Inc. was founded in 1986 and is based in Roseland, New Jersey.Flexion TherapeuticsNASDAQ:FLXNFlexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA.KadmonNYSE:KDMNKadmon is a clinical-stage biopharmaceutical company that discovers, develops and delivers transformative therapies for unmet medical needs. Its clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies.Molecular TemplatesNASDAQ:MTEMMolecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company primarily develops therapies through its proprietary biologic engineered toxin body (ETB) drug platform. The company is developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.RAPT TherapeuticsNASDAQ:RAPTRAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.